Launch Event to be Held at Alberta DermaSurgery Centre on November 17, 2016
EDMONTON, Nov. 14, 2016 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products to improve the quality of life, today announces that it will be commercially launching the Bellus
The first product to be introduced is Bellus Skin Rejuvenation Serum that has been clinically tested and validated to reduce the appearance of wrinkles and visible signs of aging. Bellus Skin Rejuvenation Serum is the only premium luxury anti-aging skin care product that combines both modified EGF and FGF1 with a transdermal delivery carrier known as Protein Transduction Domain Technology, also named SP Technology™. The patented SP Technology™ enables superior penetration of the key ingredients to the lower layers of the skin surface for optimal and long lasting effects and has been found to be superior to commonly used liposomal formulations. The sales and marketing of this product will be managed by Madenco Biosciences Inc., a subsidiary of Quest. Please visit www.bellusskin.com for more information on Bellus Skin Rejuvenation Serum.
The Company also announces that it will collaborate with Dr. Jaggi Rao, a respected dermatologist and cosmetic surgeon to help develop additional cosmetic and pharmaceutical products based on Quest's proprietary Superior Permeability or SP Technology™. By invitation only, the launch event will be held on November 17, 2016 at Rao Dermatology offices at Alberta DermaSurgery Centre.
"We are excited to launch this science based, clinically proven, premium brand cosmetic serum in Canada," said Dr. Madi R. Madiyalakan, Chief Executive Officer for Quest. "This is the first product in the Bellus Skin line introduced to be part of a complete skin care package. Quest also has distributors to market Bellus Skin in EU and ASEAN countries." Bellus Skin Serum has already been registered in EU.
"We are pleased to introduce the Bellus Skin line of cosmetic products, starting with the Bellus Skin Rejuvenation Serum, to our patients and our colleagues," said Dr. Jaggi Rao. "We are also excited to work with Quest to bring other cosmetic products based on their SP Technology™ to the market."
About Dr. Jaggi Rao
Rao Dermatology is a clinic located in Edmonton, Alberta, that provides exceptional medical and aesthetic dermatological as well as surgical care. Dr. Jaggi Rao is a double board certified dermatologist (Canada and USA) and a certified cosmetic surgeon. Dr. Rao is a full Clinical Professor of Medicine at the University of Alberta and has won several accolades for research and teaching, including the Canadian Dermatology Association's Teacher of the Year Award. He sits on the board of directors for CAAM (Canadian Association of Aesthetics Medicine) and acts as a consultant to the government (such as the Canadian Standards Association), laser and pharmaceutical industry, and professional sports teams. He is the creator and visionary behind ConsultDERM™, Canada's largest teledermatology service, allowing health care providers timely access to assistance for patients with skin-related problems. He is also the co-founder of AMT (Aesthetics Medicine Training Academy of Canada).
About Quest PharmaTech Inc. Quest PharmaTech is a publicly traded, Canadian based pharmaceutical company developing products to improve the quality of life. The Company through its subsidiary, OncoQuest is developing antibody based immunotherapeutic products for cancer. In addition, the Company owns the Photodynamic Therapy technology for oncology and dermatology applications, licensed to BioCeltran Co., Ltd., a Korea based company (Bioceltran). Quest has an ownership interest in Bioceltran which is focused on SP Technology™ for transdermal delivery of drugs and photosensitizers for pharmaceutical and cosmetic purposes. Quest also markets consumer health products worldwide, including Bellus Skin™ serum, a premium anti-wrinkle skin care product licensed from a company in South Korea. Quest is also developing an antibody licensed from University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All